Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial.
Nhu Hanh ToIsabelle Gabelle-FlandinThi My Hanh LuongGokoulakrichenane LoganadaneNabila OuidirChahrazed BoukhobzaNoémie GrellierCamille VerryAllan ThiolatJosé L CohenNina Radosevic-RobinYazid BelkacemiPublished in: Cancers (2023)
This preliminary analysis identified LB and low-TIL tumors as poor responders to the NACRT protocol, which delivered RT after several cycles of chemotherapy. These findings will allow for amending the selection of patients for the trial and help better design future trials of NACRT in BC.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radiation therapy
- phase ii study
- end stage renal disease
- clinical trial
- phase iii
- study protocol
- newly diagnosed
- ejection fraction
- phase ii
- peritoneal dialysis
- randomized controlled trial
- chronic kidney disease
- mesenchymal stem cells
- prognostic factors
- current status
- stem cells
- open label
- bone marrow
- young adults
- placebo controlled
- breast cancer risk